Cassava Sciences Reports Q3 2024 Financial and Operating Results
SAVA 11.07.2024
Drug:simufilam-UNKNOWN simufilam
Diseases:Alzheimer’s disease
Date of Upcoming Event:2024-11-07
Name of Upcoming Event:Conference Webcast
About Gravity Analytica
- Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024
$149.0 Million in Cash and Cash Equivalents atSeptember 30, 2024 . Expected To Support Operations Into 2026
- Conference Webcast Scheduled for Today at
8:30AM ET
“We look forward to the release of top-line results from RETHINK-ALZ, our first Phase 3 trial for simulfilam, by the end of 2024,” said
Current Updates on Phase 3 Clinical ProgramBackground- Our Phase 3 program consists of two global, double-blind, randomized, placebo-controlled studies of simufilam, an investigational agent in development for the potential treatment of patients with mild-to-moderate Alzheimer’s disease (“Alzheimer’s” or “AD”). The program’s goal is to evaluate the overall safety and efficacy of oral simufilam, administered twice-daily, versus placebo, in a large population of people with Alzheimer’s disease over 12 and 18 months.
The target study population is people with mild-to-moderate Alzheimer’s (mini-mental state examination, (MMSE) score of 16-27) who are biomarker-positive for Alzheimer’s disease pathology and who meet other inclusion/exclusion eligibility criteria of the study protocols.
Phase 3 Trials– Our first Phase 3 study, RETHINK-ALZ (NCT04994483), is designed to evaluate the safety and efficacy of simufilam 100 mg tablets administered twice-daily versus matching placebo over 52 weeks. Our second Phase 3 study, REFOCUS-ALZ (NCT05026177), is designed to evaluate the safety and efficacy of two doses of oral simufilam tablets, 100 mg and 50 mg, administered twice-daily, versus matching placebo, over 76 weeks. Clinical sites are in
Patient Enrollment– Both Phase 3 studies are fully enrolled. Approximately 1,900 patients are randomized in these studies, with approximately 800 patients randomized into RETHINK-ALZ and approximately 1,100 patients randomized into REFOCUS-ALZ. Approximately 90% of patients are recruited from clinical sites in the
Patient Completion –The Last Patient/Last Visit (LPLV) occurred several weeks ago for the RETHINK-ALZ study, with approximately 635 patients completed. To date, over 550 patients have completed the REFOCUS-ALZ study, for a total of over 1,185 completers.
Data and Safety Monitoring Board (DSMB) –The DSMB is composed of independent clinical research experts who periodically review interim patient safety data. Following a third routine, scheduled meeting in
Co-primary Efficacy Outcomes– The pre-specified efficacy endpoints for the Phase 3 studies are Alzheimer’s Disease Assessment Scale-Cognitive subscale 12 (ADAS-Cog12), a cognitive scale, and Alzheimer’s Disease Cooperative Study – Activities of Daily Living subscale, (ADCS-ADL), a functional scale.
Phase 3 Efficacy Results– All efficacy data from our Phase 3 program remain blinded. No interim analyses on efficacy outcomes are planned. We expect to report top-line data for RETHINK-ALZ before the end of 2024. We anticipate a top-line data readout for REFOCUS-ALZ approximately mid-year 2025.
Open-label Extension Study– This study is designed to provide no-cost access to oral simufilam to Alzheimer’s patients who have successfully completed a Phase 3 study of simufilam and who meet other entry criteria. Approximately 88% of patients who have completed treatment in one of the two Phase 3 studies, RETHINK-ALZ or REFOCUS-ALZ, have opted to enter the open-label extension (OLE) study. To date, over 1,040 patients have entered the OLE study. The OLE study is intended to continue for up to 36 months or until a new drug application for simufilam has been reviewed by FDA. Cassava also plans to add cognition and plasma biomarker monitoring to its OLE trial for patients who have completed either of the two Phase 3 trials, in order to gather additional long-term data on the potential impact of simufilam treatment.
Financial Results for Third Quarter 2024
- At
September 30, 2024 , cash and cash equivalents were$149.0 million . The Company has no debt. - Net loss was
$27.9 million or$0.58 per share. This compares to a net loss of$25.7 million , or$0.61 per share, for the same period in 2023. - Net cash used in operations was
$55.7 million during the first nine months of 2024. - Net cash used in operations for second half 2024 is expected to be
$40 to$50 million , consistent with previous guidance. In addition, the Company intends to pay a previously announced$40 million SEC investigation settlement, which has been placed in escrow and excluded from cash and cash equivalents. The Company estimates cash and cash equivalents at year-end 2024 in a range from$117 to$127 million . - Research and development (R&D) expenses were
$17.7 million . This compared to$23.6 million for the same period in 2023. R&D expenses decreased due primarily to the completion of patient screening and enrollment for our Phase 3 clinical program in the fall of 2023. Patients are continually completing the Phase 3 program and a portion of completers are enrolling in the lower cost open-label extension study. These decreases were partially offset by an increase in stock-based compensation expense due to new grant awards in the third quarter of 2024. - General and administrative (G&A) expenses were
$12.9 million . This compared to$4.3 million for the same period in 2023. G&A expenses increased significantly due primarily to higher legal related expenses, increased compensation costs, including severance, as well as an increase in stock-based compensation expense due to new grant awards in late 2023 and 2024.
Webcast DetailsDate:
About
Simufilam is an investigational oral, small molecule drug candidate currently being evaluated in two Phase 3 clinical trials for the potential treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain. Cassava Sciences believes that simufilam interrupts amyloid-β42 binding to receptors in the brain and may affect the Alzheimer's disease process.
For more information, please visit:https://www.CassavaSciences.com
For More Information Contact:
Investors
Media
Company
Cautionary Note Regarding Forward-Looking Statements:This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that may include but are not limited to statements regarding: our ability to extend our existing open-label extension trials, as contemplated or at all; the design, scope, conduct, continuation, completion, intended purpose, or future results of our on-going Phase 3 programof simufilam in patients with Alzheimer's disease; the timing of anticipated milestones; the assessment of interim safety data for the Phase 3 program at prior DSMB meetings; the treatment of people with Alzheimer’s disease the safety or efficacy of simufilam in people with Alzheimer’s disease dementia; expected cash balances and cash use in future periods; comments made by our employees regarding simufilam, drug effects, and the treatment of Alzheimer’s disease; and potential benefits, if any, of our product candidates. These statements may be identified by words such as “anticipate”, “believe”, “could”, “expect”, “forecast”, “intend”, “may”, “plan”, “possible”, “potential”, “will”, and other words and terms of similar meaning.
Such statements are based largely on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, the ability to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates,the apparent ability of simufilam to favor patients with mild Alzheimer’s disease;the apparent safety or tolerance of simufilam in our open-label clinical trials; our current expectations regarding timing of clinical data for our Phase 3 studies;any expected clinical results of Phase 3 studies; the treatment of people with Alzheimer’s disease; andcomments made by our employees regarding simufilam, drug effects, and the treatment of Alzheimer’s disease; potential benefits, if any, of our product candidates and including those described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended
All of our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world.
Our clinical results from earlier-stage clinical trials may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.
We are in the business of new drug discovery and development. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-Kand Quarterly Reports on Form 10-Qin their entirety, including the risk factors therein. Because risk is fundamental to the process of drug discovery and development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.
– Financial Tables Follow –
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (unaudited, in thousands, except per share amounts) | |||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Operating expenses | |||||||||||||||
| Research and development | $ | 17,676 | $ | 23,603 | $ | 49,107 | $ | 70,692 | |||||||
| General and administrative | 12,947 | 4,276 | 62,852 | 12,476 | |||||||||||
| Total operating expenses | 30,623 | 27,879 | 111,959 | 83,168 | |||||||||||
| Operating loss | (30,623 | ) | (27,879 | ) | (111,959 | ) | (83,168 | ) | |||||||
| Interest income | 2,618 | 2,005 | 6,710 | 6,254 | |||||||||||
| Other income, net | 62 | 223 | 321 | 616 | |||||||||||
| Gain from change in fair value of warrant liabilities | — | — | 108,183 | — | |||||||||||
| Net income (loss) | $ | (27,943 | ) | $ | (25,651 | ) | $ | 3,255 | $ | (76,298 | ) | ||||
| Net income (loss) per share, basic | $ | (0.58 | ) | $ | (0.61 | ) | $ | 0.07 | $ | (1.82 | ) | ||||
| Net income (loss) per share, diluted | (0.58 | ) | (0.61 | ) | (0.88 | ) | (1.82 | ) | |||||||
| Weighted-average shares used in computing net income (loss) per share, basic | 47,976 | 42,002 | 45,734 | 41,845 | |||||||||||
| Weighted-average shares used in computing net income (loss) per share, diluted | 47,976 | 42,002 | 46,101 | 41,845 | |||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| (unaudited, in thousands) | |||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 148,978 | $ | 121,136 | |||
| Restricted cash | 40,000 | — | |||||
| Prepaid expenses and other current assets | 13,571 | 8,497 | |||||
| Total current assets | 202,549 | 129,633 | |||||
| Property and equipment, net | 21,135 | 21,854 | |||||
| Intangible assets, net | 69 | 176 | |||||
| Total assets | $ | 223,753 | $ | 151,663 | |||
| Liabilities and stockholders' equity | |||||||
| Current liabilities | |||||||
| Accounts payable and accrued expenses | $ | 52,244 | $ | 10,573 | |||
| Accrued development expense | 2,543 | 3,037 | |||||
| Accrued compensation and benefits | 1,950 | 200 | |||||
| Other accrued liabilities | 297 | 385 | |||||
| Total current liabilities | 57,034 | 14,195 | |||||
| Other non- current liabilities | 80 | — | |||||
| Total liabilities | 57,114 | 14,195 | |||||
| Stockholders' equity | |||||||
| Common Stock and additional paid-in-capital | 544,153 | 518,237 | |||||
| Accumulated deficit | (377,514 | ) | (380,769 | ) | |||
| Total stockholders' equity | 166,639 | 137,468 | |||||
| Total liabilities and stockholders' equity | $ | 223,753 | $ | 151,663 | |||
Source: Cassava Sciences, Inc.